

# Blanca Scheijen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1451407/publications.pdf>

Version: 2024-02-01

57  
papers

2,042  
citations

331538

21  
h-index

243529

44  
g-index

58  
all docs

58  
docs citations

58  
times ranked

4127  
citing authors

#	ARTICLE	IF	CITATIONS
1	Loci Associated with N-Glycosylation of Human Immunoglobulin G Show Pleiotropy with Autoimmune Diseases and Haematological Cancers. <i>PLoS Genetics</i> , 2013, 9, e1003225.	1.5	323
2	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. <i>Leukemia</i> , 2019, 33, 2241-2253.	3.3	177
3	Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. <i>Oncogene</i> , 2002, 21, 3314-3333.	2.6	164
4	Tumor suppressors BTG1 and BTG2: Beyond growth control. <i>Journal of Cellular Physiology</i> , 2019, 234, 5379-5389.	2.0	149
5	The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. <i>Haematologica</i> , 2018, 103, 565-574.	1.7	113
6	FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. <i>Oncogene</i> , 2004, 23, 3338-3349.	2.6	108
7	Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2227-2240.	3.3	92
8	NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. <i>Blood</i> , 2004, 103, 4622-4629.	0.6	84
9	The Origin and Nature of Tightly Clustered BTG1 Deletions in Precursor B-Cell Acute Lymphoblastic Leukemia Support a Model of Multiclonal Evolution. <i>PLoS Genetics</i> , 2012, 8, e1002533.	1.5	75
10	Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. <i>Breast Cancer Research</i> , 2011, 13, R82.	2.2	74
11	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. <i>Leukemia</i> , 2019, 33, 2254-2265.	3.3	70
12	BTG1 regulates glucocorticoid receptor autoinduction in acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 4810-4819.	0.6	69
13	Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. <i>Nature Immunology</i> , 2017, 18, 694-704.	7.0	67
14	Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. <i>Haematologica</i> , 2017, 102, 541-551.	1.7	49
15	Novel developments in the pathogenesis and diagnosis of extranodal marginal zone lymphoma. <i>Journal of Hematopathology</i> , 2017, 10, 91-107.	0.2	45
16	Constitutive E2F1 Overexpression Delays Endochondral Bone Formation by Inhibiting Chondrocyte Differentiation. <i>Molecular and Cellular Biology</i> , 2003, 23, 3656-3668.	1.1	40
17	High Incidence of Thymic Epithelial Tumors in E2F2 Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 10476-10483.	1.6	31
18	Tumor suppressor BTG1 promotes PRMT1-mediated ATF4 function in response to cellular stress. <i>Oncotarget</i> , 2016, 7, 3128-3143.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Altered cerebellum development and impaired motor coordination in mice lacking the Btg1 gene: Involvement of cyclin D1. <i>Developmental Biology</i> , 2015, 408, 109-125.	0.9	28
20	Mutated Tyrosine Kinases As Therapeutic Targets In Myeloid Leukemias. <i>Advances in Experimental Medicine and Biology</i> , 2003, 532, 121-140.	0.8	27
21	Next-Generation Sequencing-Based Clonality Assessment of Ig Gene Rearrangements. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1105-1115.	1.2	25
22	Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development. <i>Haematologica</i> , 2016, 101, e272-e276.	1.7	24
23	Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance. <i>Cancers</i> , 2020, 12, 3553.	1.7	22
24	High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. <i>Blood</i> , 2019, 134, 946-950.	0.6	18
25	Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 3052.	1.7	13
26	Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma. <i>Clinical Chemistry</i> , 2021, 67, 867-875.	1.5	12
27	Targeted Deletion of Btg1 and Btg2 Results in Homeotic Transformation of the Axial Skeleton. <i>PLoS ONE</i> , 2015, 10, e0131481.	1.1	11
28	Clonality assessment and detection of clonal diversity in classic Hodgkin lymphoma by next-generation sequencing of immunoglobulin gene rearrangements. <i>Modern Pathology</i> , 2022, 35, 757-766.	2.9	11
29	<scp>DNA</scp> copy number alterations mark disease progression in paediatric chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 250-253.	1.2	9
30	Identification of novel GNAS mutations in intramuscular myxoma using next-generation sequencing with single-molecule tagged molecular inversion probes. <i>Diagnostic Pathology</i> , 2019, 14, 15.	0.9	9
31	Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies. , 2019, 2, 647-664.		9
32	Identification and Characterization of Collaborating Oncogenes in Compound Mutant Mice. , 1998, , 15-30.		8
33	Next-Generation Sequencing-Based Clonality Detection of Immunoglobulin Gene Rearrangements in B-Cell Lymphoma. <i>Methods in Molecular Biology</i> , 2022, , 7-42.	0.4	8
34	Pathways towards indolent B-cell lymphoma â€” Etiology and therapeutic strategies. <i>Blood Reviews</i> , 2017, 31, 426-435.	2.8	7
35	IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2254-2266.	2.5	7
36	Multifocal occurrence of extra-abdominal desmoid type fibromatosis â€” A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case. <i>Annals of Diagnostic Pathology</i> , 2018, 35, 38-41.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma. <i>Cancers</i> , 2022, 14, 3222.	1.7	5
38	Tumor suppressor BTG1 limits activation of BCL6 expression downstream of ETV6-RUNX1. <i>Experimental Hematology</i> , 2018, 60, 57-62.e3.	0.2	4
39	Tumor Suppressors BTG1 and IKZF1 Cooperate during Mouse Leukemia Development and Impact Relapse Rate in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 905-905.	0.6	4
40	Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. <i>Leukemia</i> , 2021, 35, 924-928.	3.3	3
41	Targeted Locus Amplification & Next Generation Sequencing for the Detection of Recurrent and Novel Gene Fusions for Improved Treatment Decisions in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 696-696.	0.6	3
42	The Leukemia-Associated Protein BTG1 Is Required for ATF4-Mediated Cellular Stress Responses. <i>Blood</i> , 2014, 124, 3587-3587.	0.6	3
43	Focal BTG1 Deletions Occur in Specific Precursor B-Cell Acute Lymphoblastic Leukemia Subtypes At Defined Hotspots Due to Aberrant V(D)J Recombination. <i>Blood</i> , 2011, 118, 399-399.	0.6	2
44	Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia. , 2006, , 93-113.		1
45	FOXO Transcription Factors Are Negatively Regulated by p38 Map Kinases Downstream of FLT3 Receptor Signaling.. <i>Blood</i> , 2005, 106, 203-203.	0.6	1
46	Deletion of IKZF1 in Pediatric Precursor-B ALL Is a Strong Prognostic Marker for Relapse.. <i>Blood</i> , 2009, 114, 1104-1104.	0.6	1
47	BTG1, a Gene Frequently Deleted in Pre-B ALL, Controls Glucocorticoid Receptor-Mediated Gene Expression.. <i>Blood</i> , 2009, 114, 3458-3458.	0.6	0
48	Tumor Suppressors BTG1 and BTG2 Fulfill Both Unique and Overlapping Functions During Normal B Lymphocyte Development. <i>Blood</i> , 2012, 120, 1303-1303.	0.6	0
49	Loss Of Tumor Suppressor BTG1 Enhances ATF4 Function and Promotes Cell Survival. <i>Blood</i> , 2013, 122, 3796-3796.	0.6	0
50	Loss Of BTG1 Function Promotes ETV6-RUNX1-Mediated Leukemic Transformation. <i>Blood</i> , 2013, 122, 2545-2545.	0.6	0
51	P190BCR-ABL1 Signaling Modulates The Function Of Tumor Suppressor Protein IKZF1. <i>Blood</i> , 2013, 122, 3809-3809.	0.6	0
52	Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 1313-1313.	0.6	0
53	Loss Of IKZF1 Function Mediates Resistance Towards Glucocorticoid-Induced Apoptosis. <i>Blood</i> , 2013, 122, 3865-3865.	0.6	0
54	B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Specific Copy Number Alterations Are Unique For Progressive Pediatric Chronic Myeloid Leukemia (CML): A Large Cohort Study. <i>Blood</i> , 2013, 122, 2715-2715.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Btg1-Deficiency Promotes ETV6-RUNX1-Mediated Leukemic Transformation By Upregulation of BCL6. Blood, 2014, 124, 5193-5193.	0.6	0
56	Tumor Suppressors Btg1 and Btg2 Regulate B Lineage Commitment through Modulation of Ebf1 Activity. Blood, 2014, 124, 4311-4311.	0.6	0
57	Glucocorticoid Resistance in IKZF1-Deleted BCP-ALL: It Is PTEN Again. Blood, 2018, 132, 4088-4088.	0.6	0